Selected publications
-
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 23 - Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 Information Resource GET IT
-
Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia.
Journal of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 96 -
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
Leukemia Research.
2017
Academic Article
GET IT
Times cited: 7 -
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study.
The Lancet Oncology.
2017
Academic Article
GET IT
Times cited: 112 -
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 82 -
Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines.
JNCCN Journal of the National Comprehensive Cancer Network.
2013
Review
GET IT
Times cited: 93 -
Acute myeloid leukemia.
JNCCN Journal of the National Comprehensive Cancer Network.
2012
Academic Article
GET IT
Times cited: 178 -
Acute myeloid leukemia: Clinical practice guidelines in oncology.
JNCCN Journal of the National Comprehensive Cancer Network.
2011
Review
GET IT
Times cited: 43